Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-11 of 11
Keywords: Toxicity
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Lindsey E. Roeker, Catherine C. Coombs, Nirav N. Shah, Wojciech Jurczak, Jennifer A. Woyach, Chan Y. Cheah, Krish Patel, Kami Maddocks, Yucai Wang, Pier Luigi Zinzani, Talha Munir, Youngil Koh, Meghan C. Thompson, Catherine E. Muehlenbein, Chunxiao Wang, Richard Sizelove, Sarang Abhyankar, Safarulla Hasanabba, Donald E. Tsai, Toby A. Eyre, Michael Wang
Journal:
Acta Haematologica
Acta Haematol 1–17.
Published Online: 05 June 2024
.... Pirtobrutinib is administered until disease progression or toxicity, necessitating an understanding of the safety profile in patients with extended treatment. Methods: Here we report the safety of pirtobrutinib in patients with relapsed/refractory B-cell malignancies with extended (≥12 months) drug exposure...
Journal Articles
Aimaz Afrough, Pearl Rajan Abraham, Laura Turer, Gurbakhash Kaur, Aishwarya Sannareddy, Doris K. Hansen, Larry D. Anderson Jr.
Journal:
Acta Haematologica
Acta Haematol 1–15.
Published Online: 08 May 2024
...), immune effector cell-associated neurotoxicity syndrome (ICANS), non-ICANS neurotoxicity, cytopenias, infections, and hypogammaglobulinemia. Key Messages: In the evolving CAR-T landscape, a primary objective is to develop innovative strategies for managing associated toxicities. Through meticulous...
Journal Articles
Seda Beyhan Sagmen, Sevda Comert, Esra Turan Erkek, Aysun Küçüköz Uzun, Coşkun Doğan, Guven Yılmaz, Nesrin Kıral, Ali Fidan, Çağla Yılmaz Haksal, Elif Torun Parmaksız
Journal:
Acta Haematologica
Acta Haematol (2019) 142 (3): 171–175.
Published Online: 27 August 2019
... and Hodgkin’s lymphoma (HL). The major limitation of bleomycin therapy is the potential for life-threatening interstitial pulmonary fibrosis. Early identification of asymptomatic patients who may develop toxicity is important. We aimed to evaluate fluorodeoxyglucose positron-emission tomography (FDG-PET/CT...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2020) 143 (2): 176–180.
Published Online: 05 June 2019
..., instructions or products referred to in the content or advertisements. Energy drink Thrombotic thrombocytopenic purpura Toxicity Case report Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy (TMA) caused by the reduced activity of ADAMTS13 (a disintegrin...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2019) 141 (3): 138–145.
Published Online: 15 February 2019
... not change over the last 40 years and remained in the range of 6–7 months. The definition of elderly is nonuniform, and chronological age is not the best marker of treatment tolerability or a predictor of treatment-related toxicity. Some patients who are fit can tolerate induction, consolidation, and even...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2019) 141 (2): 84–90.
Published Online: 10 January 2019
.... The median progression-free survival (PFS) was 47 days (range 12–1,318), the median overall survival (OS) was 1.9 years. Twenty patients (49%) died during follow-up. Grade 3–4 hematological toxicity was reported in 21 patients (51%). Relapsed vs. refractory disease, as well as a response to gemcitabine...
Journal Articles
Flávio Augusto Naoum, Breno Pannia Espósito, Lílian Piron Ruiz, Milton Artur Ruiz, Paula Yurie Tanaka, Juliana Tavora Sobreira, Rodolfo Delfini Cançado, José Carlos de Barros
Journal:
Acta Haematologica
Acta Haematol (2014) 131 (4): 222–226.
Published Online: 05 December 2013
... transplantation (HSCT). There is a concern that labile plasma iron (LPI), the redox-active form of iron, can be involved in the occurrence of toxicity and other complications commonly observed in the early post-HSCT period. In order to better understand the LPI kinetics and its determinants and implications, we...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (2013) 131 (1): 50–58.
Published Online: 19 September 2013
... Life-threatening infections Toxicity National Institutes of Health (NIH) 10.13039/100000002 Infections continue to be a serious impediment to favorable outcomes for cancer patients undergoing cytotoxic antineoplastic therapy [ 1,2 ]. Despite the availability of modern...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (1987) 78 (Suppl. 1): 136–138.
Published Online: 25 February 2009
... intraperitoneal P388 and L1210 leukaemias and a variety of solid tumours. Three sequential studies to examine the activity, toxicity and scheduling of MTZ in acute leukaemia or chronic granulocytic leukaemia in myeloid transformation were undertaken in relapsed and/or refractory disease in patients up to the age...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (1994) 91 (1): 10–15.
Published Online: 18 February 2009
...Ernest Beutler; James A. Koziol; Robert McMillan; Jack C. Sipe; John S. Romine; Carlos J. Carrera 2-Chlorodeoxyadenosine (cladribine, Leustatin®) is being used extensively in the treatment of hematologic malignancies, but relatively little is known regarding its toxicity to the normal marrow. Long...
Journal Articles
Journal:
Acta Haematologica
Acta Haematol (1998) 99 (3): 133–137.
Published Online: 11 April 1998
... results appear to parallel results obtained with post-remission therapies intensified with high-dose cytarabine. These studies provide clinical evidence that intensified induction with cytarabine in AML influences subsequent outcome but is more toxic, gives more profound myelosuppression post-remission...